Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

EFFECT OF ADDING DAPAGLIFLOZIN TO ALLOGRAFT DYSFUNCTION OF RENAL TRANSPLANTED PATIENTS: A Prospective, Randomized, Single-blinded, Placebo- Controlled Study.

NCT04743453 is registered in ClinicalTrials.gov with University of Sao Paulo General Hospital as lead sponsor.

NCT NCT04743453
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04743453 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
EFFECT OF ADDING DAPAGLIFLOZIN TO ALLOGRAFT DYSFUNCTION OF RENAL TRANSPLANTED PATIENTS: A Prospective, Randomized, Single-blinded, Placebo- Controlled Study.
Lead sponsor
University of Sao Paulo General Hospital
Phase
Phase 4
Overall status
Completed
Start date
August 17, 2021
Completion date
September 2, 2024
Enrollment
211 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes complications, diabetes mellitus, type 2, kidney transplantation